เกี่ยวกับตอนนี้
Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:
- Introduction (0:00)
- Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)
- Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)
- Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)
- CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)
- Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)
- Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)
ภาษาอังกฤษ
สหรัฐอเมริกา
สำเนาบทสนทนา 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
ค้นหาตอนที่ผ่านมา
ค้นหาตอนที่ผ่านมาของ Research To Practice | Oncology Videos
ตอนอื่นๆ ใน PODCAST นี้
Featuring a slide presentation from Dr Julia Rotow, including the following topics:
Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)
Key findings from the Phase III…
Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:
Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
Current a…
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)
Role…
Featuring perspectives from Dr Catherine C Coombs, including the following topics:
Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor …
Featuring perspectives from Prof Susana Banerjee, including the following topics:
Overview of the biology and treatment of low-grade serous ovarian cancer (0:00)
Mechanism of action of avutometinib/defactinib (10:16)
RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian…
ข้อสงวนสิทธิ์: พอดแคสต์และอาร์ตเวิร์คที่ฝังอยู่ในหน้านี้มาจาก Dr Neil Love ซึ่งเป็นทรัพย์สินของเจ้าของและไม่มีส่วนเกี่ยวข้องหรือรับรองโดย Listen Notes, Inc.
